Golden Meditech Holdings Limited (the "Company" or "Golden Meditech"; stock code: 801), together with its subsidiaries (collectively referred to as the "Group"), a leading player in integrated medical device and healthcare services in China, thanks to our strengths in innovation and market expertise, and the ability in capturing emerging market opportunities. Over the years, we have successfully established dominant positions in each market via our proven strategy to position ourselves as the "entrepreneur +operator+ cornerstone investor." This has enabled us to unleash the intrinsic value of each business unit, releasing the Group's resources to focus on operation, speeding up the uptake of market share and effectively accelerate business growth.

Golden Meditech is recognized as a first-mover in China's healthcare industry with a proven track-record in identifying, grooming and establishing dominant positions in specialist market segments within the industry, including medical devices, cord blood banking, and hospital management and related healthcare services.

The Medical Device Segment is Primarily engaged in the development, manufacture, sales and distribution of blood-related medical devices, the Group's focus is on the development of technologies for blood recovery, purification, treatment and preservation during surgery.

Our key products includes the Autologous Blood Recovery System (the "ABRS"), the first of its kind to obtain the approval of State Food and Drug Administration ("SFDA"), the Plasma Exchange System and the Accelerated Thermostatic Infusion Pump.

The Healthcare Services Segment is focusing on hospital management and related services, the Group is the first and only foreign company with a nationwide hospital management license in China. We currently manages the two largest hematology specialist hospitals in China.

We are the first and leading provider of medical insurance information management systems and back-office business process outsourcing services in China, assisting both foreign and domestic medical insurance companies in claim processing and settlement administration in China.

The Group is also the largest shareholder of the first and largest umbilical cord blood bank in China through China Cord Blood Corporation (NYSE:CO, 44%), with exclusive licenses in Beijing, Guangdong, and Shandong, and is the single largest shareholder of Cordlife Ltd, Southeast Asia's largest cord blood bank operator.

The Strategic Investment Segment includes a 37.8% equity interests in Union China National Medical Equipment Co. Ltd., the largest medical device distributor in China and a 30% of equity interests in FunTalk China Holdings Limited (NASDAQ Ticker Symbol: FTLK), a nationwide fast-moving consumer electronics distributor.